For example, paeoniflorin administration (5 mg/kg, 3 weeks, i.p.)was reported to reverse MCAO-induced depression-like behaviors in rats by enhancing CREB-BDNF signaling in the hippocampus (Hu et al., 2019) (Figure 6), suggesting that paeoniflorin administration may be a novel strategy for the treatment of post-stroke depression. Here, BDNF is linked to major depressive disorder.